Consider investing in the AI-driven pharmaceutical theme by looking at Merck (MRK), which is viewed as an undervalued play with potential for its P/E valuation multiple to expand significantly. Despite its large run-up, NVIDIA (NVDA) is presented as a core long-term holding that remains reasonably priced relative to its future growth prospects. The physical build-out of AI infrastructure creates a major opportunity in the "picks and shovels" sectors like commodities, energy, and industrials. Financials such as J.P. Morgan (JPM) and Goldman Sachs (GS) are positioned to benefit from a strong economy and future AI-driven profit margin improvements. For diversification, consider small-cap stocks through the Russell 2000 index, which is expected to see significant earnings growth next year as the market rally broadens.

AI Sector (General Theme)

• The speaker believes a major market rotation is happening, with a focus on CapEx losers and multiple compression for the AI winners in the coming year.
• The first major AI CapEx guidance cut has occurred with CoreWeave, a private data center company.
  • CoreWeave reduced its capital expenditure guidance from $20 billion down to $12-$14 billion.
  • This cut was not due to a lack of demand (which they described as "insatiable"), but because of supply bottlenecks and delays in data center build-outs (e.g., delays in "PowerShells").
• This signals a new phase of the AI revolution: a supply-constrained revolution where the bottleneck is physical infrastructure ("concrete"), not capital.
• Firms aggressively growing CapEx have historically underperformed. The high spending of AI companies raises the bar for future returns, which could lead to stock underperformance even if earnings are good.
• The speaker specifically mentions Oracle (ORCL), GE Vernova (GEV), and other AI trades as being part of both momentum and beta (volatility) factors, which is a risky correlation at a potential inflection point in the business cycle.

Takeaways

• Investors should be cautious with AI stocks trading at very high price-to-earnings (P/E) multiples. These companies are at risk of multiple compression, meaning their stock price may not grow as fast as their earnings, or could even fall, due to the high expectations already priced in.
• The CoreWeave announcement is a critical signal. The primary risk for AI hardware and infrastructure companies is no longer a lack of demand, but the physical inability to build data centers fast enough. This could lead to delayed orders and revenue recognition.
• Look for investment opportunities in the "picks and shovels" of the AI build-out that address these new bottlenecks, such as power, commodities, and physical infrastructure components.

Pharma & Healthcare Sector

• The speaker is extremely bullish on the pharmaceutical sector, stating that 2026 will be the "pharma year."
• This bullishness is driven by the massive impact Artificial Intelligence is having on drug discovery.
• AI is on the cusp of making many cancers a "chronic condition" rather than a terminal illness.
• AI can dramatically shorten the drug discovery timeline from an average of 10 years down to potentially months or weeks, and reduce development costs by 70-90%. This leads to massive profit margin expansion.
• The speaker believes AI and biotech could become the "semiconductors of healthcare."
• Pharma is currently having one of its best relative performances against the S&P 500 since 2001.

Takeaways

• The pharmaceutical sector is presented as a major, long-term investment theme driven by a fundamental technological shift (AI).
• Investors should research pharma companies that are heavily investing in and partnering with AI drug discovery platforms.
• The potential for massive margin expansion and accelerated drug development could lead to a significant re-rating (higher valuation multiples) for companies in this space. This is a long-term trend that the market is just beginning to price in.

Eli Lilly (LLY)

• Eli Lilly is highlighted as a leader in leveraging AI for drug discovery.
• The company has recently expanded its partnership with Insilico, an AI drug discovery firm, in a deal worth over $100 million.
• Lilly is also partnering with NVIDIA (NVDA) to build one of the industry's most powerful AI supercomputers for medicine discovery.
• The speaker presents a powerful analogy: Isomorphic Labs (Google's AI drug company) is the "brain," Insilico is the "hands" (engineering), and Eli Lilly is the "body" (manufacturing, clinical trials, commercialization).
• The stock chart for LLY shows a massive upward move, which the speaker attributes to the market beginning to understand the implications of its AI strategy.

Takeaways

• Eli Lilly is positioned as a primary beneficiary of the AI revolution in healthcare.
• Its strategic partnerships with key AI players like Insilico and NVIDIA validate its leadership role and suggest it is ahead of many competitors.
• The stock's strong performance indicates that the market is rewarding this strategy, but the long-term potential from AI-driven drug discovery may still not be fully priced in.

Merck (MRK)

• Merck is presented as a potential investment opportunity within the AI-pharma theme.
• The company is trading at a low multiple of 11x P/E (Price-to-Earnings).
• The speaker expects Merck's P/E multiple to expand towards the 20s over the next couple of years as it benefits from AI-driven efficiencies and drug development, similar to what has happened with other AI beneficiaries.
• Its stock chart has not yet seen the dramatic upward move that Eli Lilly's has, suggesting it may be earlier in its AI-driven re-rating journey.

Takeaways

• Merck could be an undervalued play on the AI in pharma theme.
• Its low valuation provides a potential margin of safety compared to higher-flying names in the sector.
• Investors could research Merck's specific AI drug development initiatives to gauge its progress relative to peers like Eli Lilly.

NVIDIA (NVDA)

• The speaker describes NVIDIA as "bulletproof" and argues it is a "dirt cheap stock" when looking five years into the future, given the necessary build-out of AI infrastructure.
• Unlike many tech stocks from the dot-com era, NVIDIA has already experienced multiple compression. Its P/E ratio has come down even as its earnings have soared.
• The speaker believes NVIDIA is not like Cisco during the dot-com bubble because its valuation is much more reasonable (it doesn't have a 100x P/E).

Takeaways

• Despite its massive run-up, the speaker believes NVIDIA remains a core holding for the AI theme.
• The investment thesis is based on continued, massive demand for its chips to power the AI revolution, with the valuation seen as reasonable relative to its future earnings growth.

Google (GOOGL)

• Google is a key player in the AI drug discovery revolution through its DeepMind and Isomorphic Labs subsidiaries.
• Isomorphic Labs is preparing to launch clinical trials for AI-designed drugs and is partnering with giants like Eli Lilly and Novartis.
• The speaker points to Google's stock chart, noting that it "looks like something's going on," implying positive price action ahead of major news.

Takeaways

• Google's involvement in the high-potential field of AI-driven drug discovery is a significant, potentially underappreciated part of its investment case.
• Success in this area could provide a major new growth driver for the company, diversifying it beyond advertising.

Financials Sector (JPM, GS)

• The speaker is bullish on bank stocks, viewing their strength as a sign of a healthy economy.
• J.P. Morgan (JPM) making all-time highs is a key indicator that there are no major underlying problems in the market.
• The speaker believes financials will be a major AI beneficiary next year through improvements in profit margins.
• J.P. Morgan and Goldman Sachs (GS) are highlighted as covering both the largest bank and the bank that will benefit most from a pickup in M&A and IPO activity.

Takeaways

• Strong performance in large bank stocks like JPM can be used as a barometer for the health of the overall market and economy.
• The financial sector is another area to look for "hidden" AI plays, as technology adoption can significantly boost profitability and efficiency.

Russell 2000 (Small-Cap Stocks)

• The speaker expects the Russell 2000 (an index of small-cap stocks) to have significant earnings growth next year.
• This would represent a "broadening out" of the market rally, which has so far been dominated by a few large-cap tech stocks.
• This view is supported by analysis from Francois Trahan, who highlights that stimulus and improving business cycles (as measured by PMIs) should benefit small businesses.

Takeaways

• After a long period of underperformance, small-cap stocks could be poised for a comeback.
• Investors looking for diversification away from Big Tech could consider increasing their allocation to the Russell 2000 or other small-cap funds in anticipation of an earnings recovery.

Commodities & Infrastructure Sector

• The physical build-out of AI data centers is creating massive demand for power and physical materials.
• Mentions of "power" in corporate earnings calls have surged to levels not seen since oil was heading to $150/barrel.
• Morgan Stanley is forecasting up to a 20% shortage of U.S. power for data centers through 2028.
• This is a positive driver for commodities, energy, materials, and certain industrials and utilities.
• The speaker notes that this is a "late cycle" situation where the demand for physical goods and energy follows the initial technology boom.

Takeaways

• The AI revolution is not just about software and chips; it's a massive infrastructure project.
• This creates a long-term tailwind for sectors that provide the raw materials and energy for this build-out.
• Investors should look for opportunities in energy producers, utility companies, commodity ETFs, and industrial companies involved in construction and electrical equipment.

Bitcoin (BTC) & Crypto

• The speaker is long-term bullish on Bitcoin and the crypto ecosystem but acknowledges short-term "fatigue" and price action that is correlated with struggling retail speculation.
• The long-term bullish case is built on several pillars:
  • Tokenization: The ability to turn real-world assets (like home equity) into digital tokens that can be transacted with.
  • Velocity: The speaker introduces the concept that "tokenization plus velocity" will replace leverage as the driver of economic activity. This is a fundamental shift in how the financial system works.
  • Stablecoins: The use of stablecoins is growing rapidly, especially in developing countries, creating a network effect that eventually benefits the entire crypto ecosystem, including Bitcoin.
  • Institutional Adoption: Despite weak price action, institutional capital continues to flow in via ETFs and corporate treasuries (e.g., MicroStrategy). J.P. Morgan is also rolling out its own deposit token.

Takeaways

• The investment case for Bitcoin is shifting from a simple speculative asset to a key component of a new, tokenized financial system.
• While short-term price action can be volatile, the underlying trends of institutional adoption and the growth of stablecoin networks are strong positive indicators for the long term.
• Investors should focus on the "big picture" of tokenization and its potential to unlock trillions in dormant value, rather than getting discouraged by short-term price swings.

Gold

• The speaker expresses a skeptical or bearish view on Gold.
• He challenges the consensus view among many macro investors that gold is an essential long-term holding.
• He argues that Gold has "bubble qualities" and its fundamental story is limited to currency debasement.
• The speaker is a "Bitcoin person" and seems to favor it over gold as a store of value in the new economic paradigm.

Takeaways

• Investors who hold Gold as a core part of their portfolio should question the consensus narrative.
• The speaker suggests that digital assets like Bitcoin may be a superior alternative to gold in a future defined by tokenization and digital finance, though this is a highly debated topic.